Teprotumumab

The FDA approved expanded indication language to allow the use of teprotumumab for the treatment of thyroid eye disease for any level of activity or duration, according to a press release.

Teprotumumab is associated with a greater reduction in proptosis than placebo at 24 weeks among adults with chronic thyroid eye disease and a low clinical activity score, according to topline results.

Individualized care and patient satisfaction are among the areas of emphasis in a new consensus statement on management of thyroid eye disease.

Less than 5% of adults with thyroid eye disease who completed a full course of teprotumumab therapy required an additional course of the agent, according to a presenter at the American Thyroid Association annual meeting.

CHICAGO — Commercial insurer payments for teprotumumab vary dramatically, with cost influencing access to care and cost-effectiveness, according to a study presented at the ASOPRS Fall Scientific Symposium.

CHICAGO — Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size that correlated to improved diplopia and motility, according to a presenter here.

CHICAGO — Pretreatment evaluation of fat-to-muscle ratio in thyroid eye disease will allow for the best treatment choice, a presenter here said.

CHICAGO — Since its approval in 2020, Tepezza has become a go-to treatment for moderate to severe thyroid eye disease, unseating orbital decompression as the most used treatment, according to a presenter here.

CHICAGO — Ophthalmologists should monitor patients with thyroid eye disease when they receive their COVID-19 vaccinations, according to a small case study presented at the ASOPRS Fall Scientific Symposium.

ATLANTA — In this video exclusive, Terry Smith, MD, discusses results of an analysis of clinical trial data on blood glucose effects associated with teprotumumab therapy for thyroid eye disease.